Loading...
Market
What will be the outcome of Illumina's potential reattempt to acquire Grail by end of 2025?
3
Resolution / Starting Odds
Approved without conditions • 25%
Approved with conditions • 25%
Rejected • 25%
No reattempt made • 25%
Official announcements from Illumina or Grail, financial news outlets, regulatory bodies
Story
EU Top Court Rules in Favor of Illumina in $7.1 Billion Grail Deal Probe
Sep 3, 2024, 07:52 AM
The European Union's top court has ruled in favor of Illumina, a U.S. gene sequencing company, in its legal battle against EU antitrust regulators. The court determined that the EU overstepped its authority by investigating Illumina's $7.1 billion bid for Grail, a cancer diagnostic test maker. This ruling marks a significant victory for Illumina, which had previously abandoned the $7 billion bid due to regulatory scrutiny.
View original story
Similar markets
A cancer diagnostics company • 25%
A gene sequencing company • 25%
A biotech company unrelated to cancer diagnostics • 25%
No major acquisition • 25%
Successful privatization • 25%
Abandoned privatization plan • 25%
Privatization plan still in progress • 25%
Other outcome • 25%
Brookfield Asset Management • 25%
Private Equity Firm • 25%
Pharmaceutical Company • 25%
No Acquisition • 25%
Successfully privatized • 25%
Plan abandoned • 25%
Plan delayed • 25%
Other • 25%
Accepted as is • 25%
Revised and accepted • 25%
Rejected • 25%
Withdrawn • 25%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Illumina • 25%
Bayer • 25%
Lilly • 25%
Other • 25%
Successful privatization • 25%
Abandoned privatization • 25%
New buyout offer • 25%
Other outcome • 25%
Regulatory approval • 25%
Shareholder approval • 25%
Financial considerations • 25%
Strategic realignment • 25%